India grants Novavax Covid-19 vaccine emergency use authorisation for teens
Thursday, March 24, 2022
The vaccine, also known as NVX-CoV2373, is manufactured by theunder the brand name Covovax. Last month, Novavax conducted the last stage trial of the vaccine on 2,247 Indian teenagers aged between 12 and 17, which returned an 80% efficacy rate.
Covovax is the first coronavirus to receive authorisation in India for this age group. Last week, India started vaccinating teenagers aged between 12 and 14 using the .against
President of Novavax Stanley C. Erck commented after the decision: "we're proud of this first approval in adolescents given the efficacy and safety that our data show in this population". CEO of the Serum Institute of Indiasaid it "marks another significant milestone in strengthening our immunisation efforts".
In December last year, DCGI approved Covovax for adults aged over 18 in India. Novavax is already listed for emergency use by the World Health Organization and authorised for emergency use in Indonesia, the Philippines and Bangladesh.
- "Novavax says its COVID vaccine gets India authorisation for teens" — , March 23, 2022
- "Novavax Covid vaccine gets approval for emergency use for ages 12-18" — , March 23, 2022
- Press Release: "Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India" — , March 22, 2022